Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score

StatusRecruiting

PhasePhase 4

SponsorUniversity of Michigan

Started2026-10

View on ClinicalTrials.gov ↗

Amendment history

2026-08-31

Study Status v4

Start date2026-07→2026-10

2026-06-29

Study Status v3

Start date2026-06→2026-07

2026-06-23

Study Status v2

Start date2026-04→2026-06

2026-04-10

Study Status, Contacts/Locations v1

Recruitment opened

Study sitesdetails revised at 1 of 1 site

2026-03-18

Original filing

University of Michigan

367 trials monitored

See 20 trials at risk

Heart Failure

1,854 trials monitored

See 95 trials at risk

The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: * HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score.

Trial Details

NCT Number	NCT07490067
Lead Sponsor	University of Michigan Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Heart Failure With Reduced Ejection Fraction
Enrollment	100 participants
Start Date	2026-10
Primary Completion	2029-07 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-01